Y. Luqmani

Oncology · 2005

A researcher in the Science corpus: 1 paper; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Y. Luqmani trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Rakesh K. Jain
  2. D. Hanahan
  3. G. Klement
  4. L. Hurley

Who trusts Y. Luqmani overall

  1. Zhenling Liu

Papers from Y. Luqmani's perspective

Ordered by how strongly the researchers Y. Luqmani trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
  2. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  4. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
  5. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (Journal of Clinical Investigation)
  6. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. (Journal of Clinical Investigation)
  7. Genetic contribution to variable human CYP3A-mediated metabolism. (Advanced Drug Delivery Reviews)
  8. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (New England Journal of Medicine)
  9. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. (New England Journal of Medicine)
  10. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)

Their papers